What changed today in Metabolic: 5 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
The signal
NPHLA tracked 5 new official records on this desk today: 5 trial updates.
Why this matters
GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.
What changed
- Results posted on ClinicalTrials.gov: SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity[1]
- Trial status changed to “Recruiting”: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)[2]
- New trial registered: A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or Obesity[3]
- New trial registered: Impact of Dietary Diversity on Postprandial Insulin Secretion and Metabolism[4]
- Trial status changed to “Recruiting”: Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)[5]
- Also reported by Healthcare Dive: “CVS white paper aims to pressure drugmakers to lower GLP-1 prices”.[6]
Who this affects
- Weight-management clinics
- Med spas
- Pharmacists
- Prescribers
- Medical directors
- Practice owners & operators
What to watch next
No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.
NPHLA takeaway
These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.
Source file
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.

